

# EUREKA!



American  
Urological  
Association  
Education & Research, Inc.

## Research News & Funding Digest

### NEW THIS WEEK

#### 2018 AUA Early-Career Investigators Workshop

The AUA is now accepting nominations for the [2018 Early-Career Investigators Workshop \(ECIW\)](#), to be held on October 11–13, 2018 at AUA Headquarters in Linthicum, MD. The ECIW fosters career development in urologic research by providing participants with a solid foundation for successful grant writing. ECIW activities include one-on-one mentoring sessions with scientific advisors, presentations on navigating federally-funded grant programs and opportunities to directly interact with program officers, mock peer review, presentations on developing a fundable research program and career development presentations. **The nomination deadline is March 30, 2018.**

[Learn More](#)

#### Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (Parent F32)

The purpose of the [Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Postdoctoral Fellowship \(Parent F32\)](#) is to support research training of highly promising postdoctoral candidates who have the potential to become productive, independent investigators in scientific health-related research fields relevant to the missions of the participating NIH Institutes and Centers. Applications are expected to incorporate exceptional mentorship. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. **The application deadline is April 8, 2018.**

[View FOA](#)

#### Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship (Parent F31)

The purpose of the [Ruth L. Kirschstein National Research Service Award \(NRSA\) Individual Predoctoral Fellowship \(Parent F31\) award](#) is to enable promising predoctoral students to obtain individualized, mentored research training from outstanding faculty sponsors while conducting dissertation research in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The proposed mentored research training must reflect the applicant's dissertation research project and is expected to clearly enhance the individual's potential to develop into a productive, independent research scientist. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor. **The application deadline is April 8, 2018.**

[View FOA](#)

## Specialized Centers of Research Excellence (SCORE) on Sex Differences (U54 Clinical Trial Optional)

The [Office of Research on Women's Health](#) and participating organizations and institutes seek applications for Specialized Centers of Research Excellence (SCORE) on Sex Differences. The Centers of Excellence will support interdisciplinary approaches to advance translational research on sex differences. Each SCORE institution should develop a research agenda bridging basic and clinical research underlying a health issue that is pertinent to improving the health of women. **The application deadline is April 16, 2018.**

[View FOA](#)

---

## DoD Peer Reviewed Medical Research Program: Anticipated Funding Opportunities for FY18

Although funds have not been appropriated for the [Department of Defense Peer Reviewed Medical Research Program \(PRMRP\)](#), the PRMRP recently released a pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities. **Urologic research areas funded under the PRMRP include diabetes and interstitial cystitis. The FY18 Program Announcement is anticipated to be available in April 2018.**

[Learn More](#)

---

## Save the Date - "Cellular Functions in Urology" hosted by the University of Wisconsin-Madison O'Brien Center

The [George M. O'Brien Urology Research Center at the University of Wisconsin-Madison](#) will hold its Spring Symposium titled "Cellular Functions in Urology" on **April 20-21, 2018 at the University of Wisconsin in Madison, WI.** For more information, please contact Dr. Will Ricke at [wricke@wisc.edu](mailto:wricke@wisc.edu) or Shana Peterson at [peterston@urology.wisc.edu](mailto:peterston@urology.wisc.edu).

---

## FDA Approves Apalutamide for Non-Metastatic Castration-Resistant Prostate Cancer

On February 14, 2018, the Food and Drug Administration approved apalutamide (Erleada™, Janssen Biotech, Inc.) for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC). Approval was based on a multicenter, double-blind, clinical trial (SPARTAN, NCT01946204) randomizing 1,207 patients with NM-CRPC (2:1) to receive either apalutamide, 240 mg orally once daily in combination with ADT (medical castration or surgical castration) (n=806), or placebo once daily with ADT (n=401).

[Learn More](#)

---

## Abiraterone Approved for Earlier Use in Men with Metastatic Prostate Cancer

The Food and Drug Administration (FDA) has expanded the approval of abiraterone (Zytiga®) for men with prostate cancer. The agency approved abiraterone, in combination with the steroid prednisone, for men with metastatic prostate cancer that is responsive to hormone-blocking treatments (also known as castration-sensitive) and is at high risk of progressing.

[Learn More](#)

---

## Molecular Switch Links High-Fat Diet to Prostate Cancer Metastasis

A new study in mice, [published in Nature Genetics](#), has revealed a molecular link between a high-fat diet and the growth and spread of prostate cancer. The findings raise the possibility that changes in diet could potentially improve treatment

outcomes in some men. The researchers also showed that an anti-obesity drug that targets a protein that controls fat synthesis could potentially be used to treat metastatic prostate cancer.

[Learn More](#)

## IN THE AUA

### **NIDDK/AUA Workshop on Congenital Anomalies of External Genitalia - Save the Date**

The Congenital Anomalies of External Genitalia Workshop will be held on **May 31 - June 1, 2018 at AUA Headquarters in Linthicum, MD**. This two-day meeting will bring together researchers from a range of disciplines, including pediatric urology, developmental biology, genetics & genomics, biomechanics, endocrinology, and epidemiology, with the goal of advancing basic and clinical research in hypospadias and related disorders of external genital development. Presentations and roundtable discussions of current research strategies will aim to identify key knowledge gaps and missed opportunities and to develop potential investigative solutions that will address deficiencies in the field. Basic and clinical researchers interested in the causes of hypospadias and related congenital anomalies of external genitalia are encouraged to attend. **Please contact [research@auanet.org](mailto:research@auanet.org) with any questions.**

### **Still Time to Register for the 2018 Annual Urology Advocacy Summit**

The American Urological Association will host its first independent advocacy summit on **March 12-14, 2018 in Washington D.C.** This new, AUA-led event aims to expand, strengthen and unify the voice of urology on policy matters impacting our practices and patients by bringing together a broad array of stakeholders, including patient advocates and researchers. The conference will host speakers ranging from urologists to patients, government employees and members of Congress. It will also feature training in grassroots lobbying for those new to the process, and opportunities for participants to meet with lawmakers and their staff, and officials from agencies such as the Centers for Medicare & Medicaid Services or the National Institutes of Health.

[Register Now](#)

## CONFERENCES AND WORKSHOPS

### **Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer - AdMeTech Foundation**

The **[Third Global Summit on Precision Diagnosis and Treatment of Prostate Cancer](#)** will be held in **Boston, MA on August 3-5, 2018**. This meeting is a unique multi-disciplinary forum organized to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of observation strategies (e.g., active surveillance) and novel therapeutic interventions. The goal is to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The Third Global Summit will build on the success of the First and Second Global Summits, which have emerged as the seminal events in recognizing radiogenomics – integrating imaging and molecular diagnostics – as the future of patient care.

[Learn More](#)

## FUNDING OPPORTUNITIES

### **Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed)**

As part of the [Gabriella Miller Kids First Pediatric Research Program \(Kids First\)](#), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing are available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community. **The application deadline is March 22, 2018.**

[View FOA](#)

---

## SMSNA Pfizer Fellowship in Men's Health

The [Sexual Medicine Society of North America \(SMSNA\)](#) is now accepting applications for the SMSNA Pfizer Fellowship in Men's Health. The purpose of the fellowship program is to support clinical and/or basic research in men's sexual health and foster development of expertise in the field of men's health. The funding is intended to supplement post-doctoral research activities and conference participation to present those activities. **The application deadline is April 2, 2018.**

[Learn More](#)

---

## 2018 PCF Challenge Awards for Metastatic, Lethal Prostate Cancer

The [Prostate Cancer Foundation \(PCF\)](#) is pleased to announce a Request for Team Science Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired. PCF especially seeks applications conducting research in VA hospitals where research directly affects veterans with advanced prostate cancer. The Movember Foundation will fund approximately three (3) Movember Foundation-PCF Challenge Awards from U.S.-based teams with money it has raised in the U.S. Other funding sources will support additional PCF Challenge Awards at institutions from within or outside the U.S. **The application deadline is April 23, 2018.**

[View FOA](#)

---

## NIH Underactive Bladder and Detrusor Activity in Aging

The NIH has released three Funding Opportunity Announcements (FOAs) inviting applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons. **View the FOAs below!**

- [R01 Clinical Trial Optional](#) - Application deadline: June 5, 2018.
- [R03 Clinical Trial Optional](#) - Application deadline: June 16, 2018.
- [R21 Clinical Trial Optional](#) - Application deadline: June 16, 2018.

---

## National Centers for Translational Research in Reproduction and Infertility (P50 Clinical Trial Optional)

The purpose of this FOA is to announce the re-competition of the National Centers for Translational Research in Reproduction and Infertility (NCTRI). For the purpose of this FOA, reproductive health includes both fertility/infertility and

gynecological health. The NCTRI will be administered through the Specialized Research Center (P50) award mechanism. These centers will form a national network that facilitates and accelerates bidirectional knowledge transfer between the laboratory and clinic with the ultimate goal of improving human reproductive and gynecological health through research excellence and innovation. For this FOA, applications that address the epigenetic bases of reproductive health will be strongly encouraged. Particular emphasis will be on applications that go beyond correlative studies to address possible causality and contributions of epigenomic variants to inherited reproductive health and disease. **The application deadline is June 29, 2018.**

[View FOA](#)

## Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) seeks research project (R01) grant applications describing projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. **The application deadline is June 5, 2018.**

[View FOA](#)



American  
Urological  
Association

Education & Research, Inc.



This message is brought to you by the American Urological Association (AUA).  
You may [unsubscribe](#) from future email communications of this type at any time.  
If this email is not displaying properly, please [view the online version](#).

1000 Corporate Blvd.  
Linthicum, MD 21090  
1-866-RING-AUA  
[www.AUAnet.org](http://www.AUAnet.org)

 **Canadian?** Please [provide consent](#) to continue receiving email communications.

© 2017 American Urological Association | All Rights Reserved

1000 Corporate Boulevard, Linthicum, MD 21090